Skip to content
DataLookout
Menu

NCT02839915

Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 26 versions: 26 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 19 words Show 4 more changesShow less
    • Study completion pushed from Jul 31, 2026 to Jan 31, 2027
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site details revised at 1 of 4 sites
    • Publications: details revised at 5 of 5 entries
  2. Minor Study completion date: Dec 2025 to Jul 31, 2026v25
  3. Minor Study completion date: Jan 2025 to Dec 2025v24
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 134 to confirmed 56
    • Primary completion date changed from estimate of Jan 2025 to Apr 15, 2024
    • Site details revised at 4 of 4 sites
    v23
  5. Notable Lead sponsor: Rossignol Medical Center to Southwest Autism Research & Resource Centerv22 Show 5 more changesShow less
    • Trial status: Active, Not Recruiting to Recruiting
    • Primary and study completion dates pushed to Jan 2025
    • Eligibility criteria revised
    • Site details revised at 4 of 4 sites
    • Collaborators: 5 to 4
Show 20 earlier versionsHide 20 earlier versions
  1. Notable Trial status: Suspended to Active, Not Recruitingv21
  2. Minor Study sites: 3 to 4
    • Collaborators: 6 to 5
    v20
  3. Stopped Trial status: Recruiting to Suspended Sponsor's reason: Temporary Clinical Hold / Changing Clinical Sitesv19 Show 5 more changesShow less
    • Lead sponsor: Phoenix Children's Hospital to Rossignol Medical Center
    • Eligibility criteria revised
    • Study sites: 4 to 3
    • Study description revised
    • Collaborators: 4 to 6
  4. Minor Study sites: 3 to 4v18
  5. Minor Primary endpoints revised (2)v17
  6. Notable Lead sponsor: Emory University to Phoenix Children's Hospitalv16 Show 8 more changesShow less
    • Primary completion date: Jul 2022 to Jul 1, 2023
    • Eligibility criteria expanded, about 73 words
    • Enrollment target: 162 to 134
    • Study completion date: Jul 2023 to Jul 1, 2024
    • Secondary endpoints: 4 to 1
    • Study description revised
    • Site details revised at 3 of 3 sites
    • Collaborators: 3 to 4
  7. Notable Trial status: Not Yet Recruiting to Recruitingv15 Show 4 more changesShow less
    • Primary completion date: Jun 2022 to Jul 2022
    • Study completion date: Jun 2023 to Jul 2023
    • Start date changed from estimate of Jun 2020 to Aug 13, 2020
    • Site details revised at 3 of 3 sites
  8. Notable Start date: Oct 2019 to Jun 2020v14 Show 4 more changesShow less
    • Eligibility criteria expanded, about 49 words
    • Primary endpoints: 1 to 2
    • Primary completion date: Jan 1, 2022 to Jun 2022
    • Study completion date: Jan 1, 2023 to Jun 2023
  9. Notable Start date: Jul 2019 to Oct 2019v13
  10. Notable Start date: Apr 2019 to Jul 2019v12
  11. Notable Start date: Feb 2019 to Apr 2019v11
  12. Minor Start date: Jan 2019 to Feb 2019v10
  13. Notable Start date: Nov 1, 2018 to Jan 2019
    • Eligibility criteria shortened, about 39 words
    • Study sites: 1 to 3
    • Collaborators: 2 to 3
    v9
  14. Notable Start date: Aug 20, 2018 to Nov 1, 2018v8
  15. Notable Phase: Phase 3 to Phase 2v7 Show 4 more changesShow less
    • Start date: Jun 2018 to Aug 20, 2018
    • Enrollment target: 160 to 162
    • Study description revised
    • Study title expanded, about 4 words
  16. Notable Start date: Jan 2018 to Jun 2018
    • Collaborators revised (2)
    v6
  17. Notable Start date: Nov 1, 2017 to Jan 2018v5
  18. Notable Primary completion date: Jan 2021 to Jan 1, 2022
    • Start date: Nov 2016 to Nov 1, 2017
    • Study completion date: Jan 2022 to Jan 1, 2023
    v4
  19. Notable Eligibility criteria expanded, about 18 words
    • Primary endpoint revised
    • Secondary endpoints: details revised at 1 of 4 entries
    v3
  20. Notable Primary endpoint revised
    • Secondary endpoints: 3 to 4
    • Study description shortened, about 1,839 words
    v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in Clinical Evaluation of Language Fundamentals 4 (CELF-4) Score.
Timeframe: Screening, Week 12
Change in Clinical Evaluation of Language Fundamentals Preschool (CELF-P) score
Timeframe: Screening, Week 12

Secondary (1)

Change in Clinician Global Impression for Improvement (CGI-I) Score

Arms and interventions

Folinic AcidExperimental

Subjects randomized to receive Folinic Acid will take Liquid levo-leucovorin via oral route. The target dose is 1 mg/kg/day with a maximum of 25 mg/day, divided in two daily doses. A two- to four-week supply of 15 ml vials will be dispensed in line with the visit schedule. With the exception of children in the lowest weight group (≥ 15 - \< 20 kg) from days 1-14, parents will administer the prescribed dose twice a day at the same time each day.

Placebo ControlPlacebo comparator

Subjects randomized to receive placebo will take placebo twice a day (Exception: children in the lowest weight group ( ≥ 15 - \< 20 kg) will start once a day for Days1-13). The pattern of dose escalation will be the same as the active compound. After 12 weeks, the blind will not be broken and subjects will be offered treatment for a 12-week open-label extension phase.

Drugs: Folinic Acid

Other: Placebo

Sites

4 sites in 1 country